Foundation models (FMs), which are deep learning models pretrained on large-scale data and applied to diverse downstream ...

Leveraging an AI-powered omnimodal foundation model to accelerate drug discovery, optimize patient stratification, and de-risk clinical developmentWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a ...

Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich Leukemia ...

A high-throughput workflow integrates DNA methylation and RNA sequencing in single cells, enabling more complete insights ...

April 06, 2026) Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich ...

Rhys Parry is a research fellow in the School of Chemistry and Molecular Biosciences at the University of Queensland in Brisbane, Australia. I didn’t set out to build a career on other people’s data.

Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers ...

Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.

BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced an oral presentation at the United States and Canadian Academy of Pathology (USCAP) 115th Annual ...

The editorial, "Dynamics-driven medical big data mining: dynamic approaches to early disease forecasting and individualized care," published in Intelligent Medicine (February 2026, Volume 6, Issue 1), ...